Quanterix Study in JAMA Validates Multi-Biomarker Approach for Early Alzheimer’s Risk Assessment
Event summary
- Quanterix published a JAMA study showing multi-analyte blood tests improve Alzheimer’s risk prediction over single biomarkers.
- The study followed 300 individuals for up to 15 years, achieving a C-index of 0.90 for identifying early-stage progression.
- Quanterix’s LucentAD Complete test uses the same biomarkers validated in the study for amyloid pathology risk assessment.
- The company acquired Akoya Biosciences in 2025, adding spatial biology capabilities to its diagnostic platform.
The big picture
The study reinforces the shift toward multi-analyte diagnostics in neurodegenerative disease, aligning with broader trends in personalized medicine. Quanterix’s acquisition of Akoya Biosciences positions it uniquely to integrate blood and tissue biomarkers, potentially expanding its diagnostic reach. The findings could accelerate clinical trial enrollment and early intervention strategies for Alzheimer’s.
What we're watching
- Clinical Adoption
- How quickly LucentAD Complete gains traction in clinical settings for early Alzheimer’s risk assessment.
- Competitive Positioning
- Whether Quanterix can sustain leadership in multi-analyte diagnostics amid growing competition.
- Regulatory Pathways
- The pace at which multi-biomarker tests like LucentAD Complete secure broader regulatory approvals.
Related topics